Under 21 CFR 312, an IND must be in effect before human studies of an investigational drug can begin in the United States (with limited exceptions). The IND includes preclinical data, manufacturing information, and clinical protocols.
IND-regulated studies must be conducted under Good Clinical Practice (GCP) and reviewed by an IRB complying with 21 CFR 56.